Compare LBRX & AMSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | AMSC |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | 400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2025 | 2012 |
| Metric | LBRX | AMSC |
|---|---|---|
| Price | $47.00 | $28.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $46.60 | ★ $52.00 |
| AVG Volume (30 Days) | 285.4K | ★ 611.1K |
| Earning Date | 05-06-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 98.22 | ★ 1806.25 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $900,000.00 |
| Revenue This Year | N/A | $34.98 |
| Revenue Next Year | N/A | $21.38 |
| P/E Ratio | ★ N/A | $145.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $24.87 |
| 52 Week High | $50.16 | $70.49 |
| Indicator | LBRX | AMSC |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 40.32 |
| Support Level | $21.90 | $28.78 |
| Resistance Level | $49.65 | $33.70 |
| Average True Range (ATR) | 2.02 | 1.12 |
| MACD | -0.53 | 0.03 |
| Stochastic Oscillator | 30.43 | 31.43 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.